

## **BioLife Solutions Inc. Completes Relocation to Bothell, Washington Move to Seattle-Area Biotech Hub Improves Customer Service, Access to Researchers**

PRNewswire-FirstCall  
BOTHELL, WA

BioLife Solutions Inc. (BULLETIN BOARD: BLFS) , a leading developer and manufacturer of proprietary liquid preservation media for cells, tissues, and organs, today announced it completed the relocation of its corporate office and operations, except production, to a biotech campus in Bothell, WA, a suburb of Seattle.

Chief Executive Mike Rice remarked: "Our strategic planning process identified areas for optimizing our infrastructure to best execute our growth strategies. And this move allows us to better serve all of our customers and enhance collaborations with leading research centers, including the University of Washington and the Fred Hutchinson Cancer Research Center."

Production of BioLife's patented preservation media products will continue in Owego, NY. The Company is also evaluating several contract manufacturers to augment production capacity to meet future demand for its products.

As part of its expanded sales and marketing strategy, BioLife will be exhibiting and presenting at the following events:

- \* BIO 2007 annual international convention, May 6-9 in Boston
- \* American Society of Gene Therapy (ASGT) annual meeting, May 30-June 3 in Seattle
- \* International Society for Stem Cell Research (ISSCR) annual meeting, June 17-21 in Cairns, Australia
- \* International Society for Cellular Therapy (ISCT) annual meeting, June 24-27 in Sydney, Australia

About BioLife Solutions

BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor™ preservation media are marketed to companies, laboratories, and academic institutions engaged in research and commercial clinical applications. BioLife's line of serum-free and protein-free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function.

For more information please visit BioLife Solutions' website at [www.biolifesolutions.com](http://www.biolifesolutions.com).

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of

developments occurring after the date of this press release.

Media Relations Contact:	Investor Relations Contacts:
Len Hall	Matt Clawson or Dan Matsui
Allen & Caron, Inc.	Allen & Caron, Inc.
(949) 474-4300	(949) 474-4300
len@allencaron.com	matt@allencaron.com

SOURCE: BioLife Solutions Inc.

CONTACT: Media Relations, Len Hall, len@allencaron.com; or Investor Relations, Matt Clawson, matt@allencaron.com, or Dan Matsui, all of Allen & Caron, Inc., +1-949-474-4300

Web site: <http://www.biolifesolutions.com/>

---

<https://investors.biolifesolutions.com/2007-04-30-BioLife-Solutions-Inc-Completes-Relocation-to-Bothell-Washington>